Jefferies on Monday downgraded biopharmaceutical company Ipsen (IPN.PA) to underperform from hold and increased its price target to 135.00 euros from 117.00 euros.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)